Phospho-IRAK1 (T387) Antibody

What is the functional significance of IRAK1 T387 phosphorylation in immune signaling?

IRAK1 phosphorylation involves a sequential process critical for immune response activation. IRAK1 is initially phosphorylated by IRAK4 at Thr209, which weakly activates the kinase. Subsequently, IRAK1 autophosphorylates at Thr387 within the activation loop to achieve full activation . This autophosphorylation is essential for complete IRAK1 function in Toll-like receptor (TLR) and IL-1R signaling pathways, where it acts as a critical mediator that initiates innate immune responses against pathogens . Functionally, this phosphorylation enables IRAK1 to phosphorylate downstream targets including E3 ubiquitin ligases (Pellino proteins) and interferon regulatory factor 7 (IRF7), ultimately leading to NF-kappa-B activation and type I interferon gene transcription .

How can I validate the specificity of phospho-IRAK1 (T387) antibodies in my experimental system?

Validating phospho-specific antibodies requires multiple complementary approaches:

• Genetic validation: Test antibody reactivity in IRAK1-knockout (IRAK1−/−) cells compared to wild-type controls. The absence of signal in knockout cells confirms specificity, as demonstrated in multiple studies .

• Phosphomutant controls: Express IRAK1 wild-type (WT) and phospho-mutant (T387A) variants in IRAK1−/− cells. A true phospho-specific antibody will detect the WT protein but not the T387A mutant, which lacks the target threonine phosphorylation site .

• Kinase-dead controls: Include kinase-dead (KD) IRAK1 variants that lack catalytic activity. Since T387 phosphorylation is an autophosphorylation event, kinase-dead variants should show reduced or absent signal .

• Phosphomimetic variants: Phosphomimetic IRAK1 T209D enhances immunoreactivity compared to WT protein, providing additional validation of phosphorylation-dependent recognition .

• Stimulus-dependent detection: Confirm that signals increase following appropriate stimuli (e.g., IL-1β treatment or irradiation) that are known to activate IRAK1 .

What are the recommended applications for phospho-IRAK1 (T387) antibodies?

Phospho-IRAK1 (T387) antibodies can be utilized across multiple experimental platforms:

• Immunofluorescence (IF): Enables visualization of subcellular localization changes of phosphorylated IRAK1, with typical dilutions ranging from 1:200-1:1000 . This application has been particularly valuable for tracking the nuclear translocation of activated IRAK1 following irradiation .

• Western Blotting (WB): Allows quantitative assessment of phosphorylation levels in cell and tissue lysates . The expected molecular weight of human IRAK1 is approximately 77 kDa .

• ELISA: Useful for high-throughput quantitative analysis with recommended dilutions around 1:5000 .

• Immunohistochemistry (IHC): Some antibodies are validated for both paraffin sections (IHC-p) and frozen sections (IHC-f) of tissue samples , enabling translational research and clinical specimen analysis.

How does the subcellular localization of phosphorylated IRAK1 at T387 change in response to different stimuli?

Phosphorylated IRAK1 demonstrates distinct stimulus-dependent localization patterns with important functional implications:

• IL-1β stimulation: Following IL-1β treatment, phosphorylated IRAK1 (pThr209) localizes primarily at the inner cell periphery, consistent with its activation at cell surface receptors through MyDDosome formation at ligated IL-1Rs .

• Ionizing radiation (IR): In contrast, IR induces a dramatically different localization pattern of activated IRAK1. Initially (5 min post-IR), IRAK1-pThr209 is detected in the cytoplasm. By 15 minutes post-IR, it localizes exclusively to the nucleus, demonstrating a rapid nuclear translocation mechanism .

• Nucleolar targeting: IRAK1-pThr387 (fully activated form) exhibits a specific spatial and temporal distribution within the nucleoplasm after irradiation. The signal is first detected at the inner nuclear periphery, then spreads throughout the nucleoplasm, and eventually concentrates in nucleoli (identified by co-staining with nucleolin and fibrillarin) . This nucleolar targeting is specific to fully activated IRAK1 (pThr387), as partially activated IRAK1 (pThr209) remains dispersed in the nucleoplasm .

These distinct localization patterns suggest different functional roles for IRAK1 in cytokine signaling versus DNA damage response pathways.

What are the structural implications of T387 phosphorylation on IRAK1 kinase activity?

The structural basis of IRAK1 activation through T387 phosphorylation presents interesting paradoxes:

Crystal structure analysis of the IRAK1 kinase domain revealed that it adopts an active conformation even in the absence of phosphorylation at T209 or T387, as defined by the presence of an assembled regulatory spine and the salt bridge between K239 of β3 and E259 of αC . This raises questions about the structural necessity of T387 phosphorylation for kinase activation.

Several mechanistic explanations have been proposed:

• Autoinhibition relief: In full-length IRAK1, the N-terminal death domain likely exerts autoinhibition on the kinase domain. T387 phosphorylation may be required to release this autoinhibition rather than directly altering the kinase domain structure .

• Structural accessibility: Analysis shows that T387 is highly exposed to solvent, and its phosphorylation is unlikely to significantly alter kinase domain conformation . In contrast, T209 forms intimate interactions with surrounding atoms and would likely require conformational changes for phosphorylation to occur .

• Signaling specificity: While recombinant IRAK1 kinase domain shows similar activity to IRAK4 kinase domain in vitro without phosphorylation, phosphorylation at T387 may direct substrate specificity or protein-protein interactions in vivo .

• Nucleolar targeting: T387 phosphorylation appears critical for nucleolar targeting of IRAK1 following irradiation, suggesting it may regulate protein interactions or nuclear retention rather than just catalytic activity .

These structural considerations highlight the complex multi-level regulation of IRAK1 beyond simple on/off kinase activation.

How do mutations at the T387 site affect IRAK1 function in DNA damage response pathways?

Mutation studies have provided critical insights into T387's role in IRAK1-mediated DNA damage responses:

These mutational studies collectively demonstrate that both T387 phosphorylation and proper subcellular localization are essential for IRAK1's role in DNA damage response.

What methodological approaches can help distinguish between IRAK1's roles in immune signaling versus DNA damage response?

Differentiating between IRAK1's dual functions requires careful experimental design:

• Stimulus-specific activation: Compare IL-1β treatment (activating canonical immune signaling) with ionizing radiation (IR) to distinguish pathway-specific responses. The distinct subcellular localization patterns (cell periphery vs. nuclear) provide a visual marker of pathway engagement .

• Temporal analysis: Track the kinetics of IRAK1 activation and localization, as IL-1β and IR induce different temporal patterns of phosphorylation and translocation .

• Separation-of-function mutants: Utilize IRAK1 R4A, which specifically disrupts nuclear targeting while preserving catalytic activity. This mutant allows researchers to uncouple nuclear functions from cytoplasmic signaling .

• Pathway-specific readouts: Monitor NF-κB activation for immune signaling versus DNA damage markers (γH2AX, 53BP1) for radiation response .

• Cell type comparisons: Compare immune cells (where canonical signaling predominates) with cancer cell lines that exhibit radioresistance, where the DNA damage response pathway may be more prominent .

• Genetic models: Utilize Irak1 knockin mice with specific mutations (e.g., D359A) that selectively impact certain IRAK1 functions while preserving others .

• Combined immunotherapy and radiotherapy models: Test IRAK1 inhibitors in combination with radiation and TLR agonists to dissect pathway-specific effects in cancer models .

These approaches have revealed that IRAK1 inhibition can radiosensitize certain cancers without completely abolishing beneficial immune responses, suggesting differential requirements for IRAK1 catalytic activity in these pathways .

How is phospho-IRAK1 (T387) status correlated with cancer radioresistance?

Emerging evidence links IRAK1 activation to radiotherapy resistance in cancer:

These findings suggest phospho-IRAK1 could serve as both a biomarker to identify patients who might benefit from combined IRAK1 inhibition and radiotherapy, as well as a direct therapeutic target.

What are the current methodological challenges in targeting IRAK1 T387 phosphorylation for therapeutic purposes?

Developing therapeutic strategies targeting IRAK1 T387 phosphorylation faces several technical and biological challenges:

• Pathway selectivity: The involvement of IRAK1 in both immune signaling and DNA damage response creates a challenge in selectively targeting its role in radioresistance without compromising beneficial immune functions . Current evidence suggests that catalytic inhibitors might preferentially affect the DNA damage response pathway while preserving some immune functions, but more selective approaches are needed .

• Phosphorylation specificity: Direct targeting of T387 phosphorylation (rather than general kinase inhibition) would require novel therapeutic modalities, as phosphorylation sites are traditionally difficult to target with small molecules. Approaches might include degraders specific to the phosphorylated form or disruptors of protein-protein interactions dependent on this modification.

• Nuclear translocation: IRAK1 must translocate to the nucleus following irradiation to mediate radioresistance . Compounds that selectively inhibit this translocation represent an untapped therapeutic opportunity but require different screening approaches than traditional kinase inhibitor development.

• Biomarker development: While phospho-IRAK1 antibodies work well in research settings, developing clinical-grade assays to identify patients with activated IRAK1 signaling remains challenging. Standardization of phospho-specific immunohistochemistry protocols for patient stratification is needed .

• Combination strategies: Optimal integration of IRAK1 inhibition with radiotherapy and potentially immunotherapy requires careful timing and sequencing to maximize tumor cell killing while preserving anti-tumor immune responses. Preclinical models suggest that IRAK1 inhibition combined with TLR agonist-based immunotherapy could provide a "one-two punch" against tumors .

Addressing these challenges requires interdisciplinary approaches combining structural biology, chemical biology, immunology, and radiation oncology to develop next-generation IRAK1-targeted therapeutics.

What are the emerging methods for studying the temporal dynamics of IRAK1 T387 phosphorylation?

Advanced techniques to investigate IRAK1 T387 phosphorylation dynamics include:

• Live-cell imaging: Development of fluorescent biosensors that can detect T387 phosphorylation in real-time would enable visualization of activation kinetics in living cells. While challenging, such approaches have been successful for other kinases and could be applied to IRAK1.

• Mass spectrometry-based phosphoproteomics: Quantitative MS techniques can track multiple IRAK1 phosphorylation sites simultaneously, providing insight into the sequence and stoichiometry of modifications following different stimuli .

• Single-cell phospho-flow cytometry: This technique could enable analysis of IRAK1 activation heterogeneity within cell populations, particularly important in tumor microenvironments where radiation effects may be non-uniform.

• Spatial proteomics: Combining subcellular fractionation with phospho-specific detection can track IRAK1's movement between cellular compartments, particularly important given its dramatic translocation from cytoplasm to nucleolus following irradiation .

• Proximity labeling: Techniques like BioID or TurboID coupled with phospho-specific antibodies could identify different interaction partners of IRAK1 depending on its phosphorylation state and subcellular location.

• Intravital microscopy: As demonstrated in zebrafish models, phospho-IRAK1 can be visualized in living organisms following irradiation , suggesting potential for tracking activation dynamics in more complex in vivo settings.

These emerging technologies promise to reveal new insights into how IRAK1 phosphorylation is regulated in space and time, potentially identifying critical vulnerabilities in radioresistant cancers.

How does the interplay between different IRAK1 phosphorylation sites regulate its diverse cellular functions?

IRAK1 function is regulated by a complex network of phosphorylation events:

Future studies systematically analyzing how different phosphorylation patterns direct IRAK1 to specific signaling outputs will be crucial for developing targeted therapeutic approaches that selectively modulate certain IRAK1 functions while preserving others.